Retail Clinics

  • Cirrus targets ear-ringing with Tinnitex

    COLD SPRING HARBOR, N.Y. Cirrus Healthcare Products has expanded its ear care offerings with a new product, slated to hit retail shelves in spring 2011.

    Tinnitex is the first and only earplug to help relieve tinnitus, a condition that causes ringing in the ears, the company said. According to the Journal of Clinical Nursing, more than 50 million Americans suffer from tinnitus.

  • FDA: Mouth rinse products cannot have 'prevents gum disease' claim

    SILVER SPRING, Md. The Food and Drug Administration on Tuesday issued warning letters to three companies that manufacture and market mouth rinse products with claims that they remove plaque above the gum line or promote healthy gums. According to the FDA, these claims suggested the products are effective in preventing gum disease when no such benefit has been demonstrated.

    Warning letters were sent to: Johnson & Johnson (Listerine total care anti-cavity mouthwash), CVS (CVS complete care anti-cavity mouthwash), and Walgreens (Walgreen mouth rinse full action).

  • GSK Consumer Healthcare to FDA: Smoke out smokeless tobacco products

    PARSIPPANY, N.J. GlaxoSmithKline Consumer Healthcare is urging the Food and Drug Administration to remove smokeless tobacco products from the market.

  • RediClinic offers two flu vaccination options

    HOUSTON The Centers for Disease Control and Prevention now is recommending that everybody older than 6 months of age get vaccinated for the flu, as the flu has begun appearing in various states and last year’s H1N1 flu is expected to appear again.

     

    In response, RediClinic is offering two options for vaccination: the traditional injectable vaccine and a nasal spray version.

     

     

  • Target-funded study highlights cost of hunger in Minnesota

    ST. PAUL, Minn. — A Target-funded study, conducted by the University of Minnesota Food Industry Center, found that hunger costs Minnesota residents more than $1.62 billion annually in direct and indirect health and education costs.

  • Atkins Nutritionals expands three lines with new offerings

    DENVER Weight-management products maker Atkins Nutritionals has introduced five new products for its Advantage, Day Break and Endulge lines.

  • Now available at Rite Aid: Pertussis immunizations

    CAMP HILL, Pa. One week after Walgreens announced that it was offering pertussis immunizations at its California locations, Rite Aid has followed suit.

    Rite Aid said Monday that pharmacists at more than 500 Rite Aid stores across the state will offer pertussis, or whooping cough, vaccinations to individuals ages 7 years and older. The disease already has claimed the lives of nine infants in the state and is on pace to become the worst epidemic the state has seen in 50 years.

  • Pfizer recalls lot of ThermaCare HeatWraps Menstrual

    NEW YORK Pfizer’s over-the-counter division recalled one lot of a ThermaCare product over the possibility of leaks.

     

    Pfizer Consumer Healthcare announced Friday the voluntary recall of lot number E06931 of its ThermaCare HeatWraps Menstrual product and notified the Food and Drug Administration.

     

     

    The company said possible leaks in the wraps could cause skin injury, such as irritation and burning.

     

  • Alcon's TobraDex ST treats inflammatory eye conditions

    HUENENBERG, Switzerland Eyecare company Alcon has launched a new drug for inflammatory eye conditions.

     

    Alcon announced the launch of TobraDex ST (tobramycin, dexamethasone ophthalmic suspension) in the 0.3%/0.5% strength. The drug is used to treat inflammatory eye conditions treatable with corticosteroids and where bacterial infection or risk of infection exists.

     

     

  • FDA to allow GSK’s Avandia, with restrictions

    SILVER SPRING, Md. The Food and Drug Administration has moved to significantly restrict access to a controversial diabetes drug made by GlaxoSmithKline.

    The agency said Thursday that it would restrict access to the Type 2 diabetes medication Avandia (rosiglitazone) in response to clinical study data suggesting that its use can increase the risk of heart attacks and strokes.

X
This ad will auto-close in 10 seconds